Web Analytics


Our publications:
English
Our publications
Home Tags Posts tagged with "O’Melveny"

Tag: O’Melveny

White & Case hires M&A partner Alan Bao for Beijing office

O’Melveny’s M&A partner Alan Bao has joined White & Case’s Beijing office as a partner to strengthen its corporate practice

Tiantu debuts as first Chinese PE/VC firm to list on HKEX

O’Melveny, Grandall, Carey Olsen, HSF and Jia Yuan assisted Tiantu Capital in completing its USD144 million IPO on HKEX, making it the first mainland PE/VC company to list in the city

Cancer drug firm Adlai Nortye raises USD97.5m in Nasdaq IPO

O’Melveny, Han Kun Law Offices, Maples Group, Latham & Watkins and Zhong Lun Law Firm advised on cancer drug developer Adlai Nortye’s Nasdaq debut

Fourth Paradigm clinches HKD1.02bn IPO on fourth endeavour

China’s AI unicorn Fourth Paradigm, after three previous attempts, has successfully listed on the HKEX raising HKD1.02 billion (USD130 million)

Luzhu Biotechnology launches HKD341m IPO via chapter 18A

Luzhu Biotechnology debuted on the HKEX through chapter 18A, the first biotech company without any revenue or profits to be listed this year, raising USD43.45 million

Morrison Foerster grows China’s private equity and M&A practice

Morrison Foerster has expanded its private equity and M&A operation in China with the hiring of partner Zhao Rongjing from Kirkland & Ellis

O’Melveny acts on Acotec Scientific’s partial offering

O’Melveny advised China’s medical technology company, Acotec Scientific Holdings, on the voluntary partial offer for a majority stake of up to 65% by US-listed Boston Scientific Group

3D Medicines taps Han Kun for IP advice in Hong Kong IPO

3D Medicines, an oncology medical research and development company, tapped Han Kun Law Firm’s intellectual property services during preparations for its HKD430 million Hong Kong IPO, to protect multiple patented drugs

Law firm quartet advises Gaush Meditech’s Hong Kong listing

Gaush Meditech, the fourth largest ophthalmic medical device company in China, raised HKD672 million (USD86.34 million) in its Hong Kong listing, offering a total of 13.06 million shares at HKD51.4 per share

China Business Law Awards 2022

China Business Law Journal reveals the law firms that have excelled in the past year

MOST READ ON VANTAGE ASIA

securing patient information

Health provider obligations in securing patient information

By Mathew Chacko, Aadya Misra and Shambhavi Mishra, Spice Route Legal
AI in Tax Compliance

AI perhaps making tax regimes more transparent

By Mukesh Butani and Pranoy Goswami, BMR Legal

Loss of electricity generation claims in new energy projects

By Wang Yong, DOCVIT Law Firm

Correspondents

Compliance strategy

How consumer, retail companies can capture compliance and profits

By Quan Kaiming and Yuan Wei, AllBright Law Offices

Product-by-process claim lesson in appeal judgment

By Pravin Anand, Vaishali Mittal, and Siddhant Chamola, Anand and Anand
DSO criminal compliance obligations

New laws tighten DSOs’ criminal compliance obligations

By Ekin Zeng and Chen Yitao, AllBright Law Offices

Join our mailing list for legal news and alerts

Sign up